Search in:

Acta Cardiologica Volume 78, 2023 - Issue 7

Submit an article Journal homepage

Views

CrossRef citations to date

Altmetric

Letters to the Editor

Durable LVAD in a SLE patient – no anticoagulation for >6 years

Nandini A. Raya Division of Cardiology, Department of Medicine, Texas Tech Health Sciences Center, Lubbock, TX, USA

https://orcid.org/0000-0002-9155-2729

Nandini Naira Division of Cardiology, Department of Medicine, Texas Tech Health Sciences Center, Lubbock, TX, USA;b Division of Cardiology, Penn State Health, Milton S Hershey Medical Center, Hershey, PA, USACorrespondence[email protected]

https://orcid.org/0000-0002-1243-4389

Pages 854-857 | Received 09 Jun 2023, Accepted 19 Jun 2023, Published online: 28 Jun 2023

Cite this article
https://doi.org/10.1080/00015385.2023.2230024
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

References

Eisen HJ. Left ventricular assist devices (LVADS): history, clinical application and complications. Korean Circ J. 2019;49(7):568–585. doi: 10.4070/kcj.2019.0161.
PubMed Web of Science ®Google Scholar
Frigerio M. Left ventricular assist device: indication, timing, and management. Heart Fail Clin. 2021;17(4):619–634. doi: 10.1016/j.hfc.2021.05.007.
PubMed Web of Science ®Google Scholar
Varshney AS, DeFilippis EM, Cowger JA, et al. Trends and outcomes of left ventricular assist device therapy: JACC focus seminar. J Am Coll Cardiol. 2022;79(11):1092–1107. doi: 10.1016/j.jacc.2022.01.017.
PubMed Web of Science ®Google Scholar
Mistiaen WP. Heart transplantation in patients with previous malignancy. An overview. Acta Cardiol. 2015;70(2):123–130. doi: 10.1080/ac.70.2.3073502.
PubMed Web of Science ®Google Scholar
Yildiz O, Baydar O. Prognostic value of pulmonary artery pulsatility index in chronic heart failure patients with reduced ejection fraction. Acta Cardiol. 2022;77(5):408–415. doi: 10.1080/00015385.2021.1950369.
PubMed Web of Science ®Google Scholar
Lamotte MX, Chimenti S, Deboeck G, et al. Left ventricular assist device: exercise capacity evolution and rehabilitation added value. Acta Cardiol. 2018;73(3):248–255. doi: 10.1080/00015385.2017.1368947.
PubMed Web of Science ®Google Scholar
Sayin OA, Ozpeker C, Schoenbrodt M, et al. Ventricular assist devices in patients with chemotherapy-induced cardiomyopathy: new modalities. Acta Cardiol. 2015;70(4):430–434. doi: 10.1080/ac.70.4.3094652.
PubMed Web of Science ®Google Scholar
Rossi M, Serraino GF, Jiritano F, et al. What is the optimal anticoagulation in patients with a left ventricular assist device? Interact Cardiovasc Thorac Surg. 2012;15(4):733–740. doi: 10.1093/icvts/ivs297.
PubMed Web of Science ®Google Scholar
Gerrald JE, Ather A, Schadler A, et al. Retrospective review of secondary prevention strategies for gastrointestinal bleeding and associated clinical outcomes in left ventricular assist device patients. Artif Organs. 2022;46(12):2423–2431. doi: 10.1111/aor.14316.
PubMed Web of Science ®Google Scholar
Dufendach KA, Seese L, Stearns B, et al. Outcomes of left ventricular assist device implantation in hypercoagulable patients. J Card Surg. 2020;35(9):2201–2207. doi: 10.1111/jocs.14710.
PubMed Web of Science ®Google Scholar
Ray NA, Nair N. Long-term left ventricular device support in a patient with systemic Lupus erythematosis. J Am Coll Cardiol. 2022;79(9):2676. doi: 10.1016/S0735-1097(22)03667-1.
Web of Science ®Google Scholar
Gage A, Blumer V, Joyce E. Lupus and left ventricular assist devices: high-risk for bleeding? Asaio J. 2019;65(8):e95–e96. doi: 10.1097/MAT.0000000000000946.
PubMed Web of Science ®Google Scholar
Kim CH, Al-Kindi SG, Jandali B, et al. Incidence and risk of heart failure in systemic lupus erythematosus. Heart. 2017;103(3):227–233. doi: 10.1136/heartjnl-2016-309561.
PubMed Web of Science ®Google Scholar
Schibilsky D, Takatani S, Schibilsky B, et al. Hemocompatibility of new magnetically-levitated centrifugal pump technology compared to the CentriMag adult pump. Sci Rep. 2020;10(1):22055. doi: 10.1038/s41598-020-78709-0.
PubMed Web of Science ®Google Scholar
Schibilsky D, Lenglinger M, Avci-Adali M, et al. Hemocompatibility of axial versus centrifugal pump technology in mechanical circulatory support devices. Artif Organs. 2015;39(8):723–728. doi: 10.1111/aor.12544.
PubMed Web of Science ®Google Scholar
Uriel N, Colombo PC, Cleveland JC, et al. Hemocompatibility-related outcomes in the MOMENTUM 3 trial at 6 months: a randomized controlled study of a fully magnetically levitated pump in advanced heart failure. Circulation. 2017;135(21):2003–2012. doi: 10.1161/CIRCULATIONAHA.117.028303.
PubMed Web of Science ®Google Scholar
Pereira NL, Chen D, Kushwaha SS, et al. Discontinuation of antithrombotic therapy for a year or more in patients with continuous-flow left ventricular assist devices. Interact Cardiovasc Thorac Surg. 2010;11(4):503–505. doi: 10.1510/icvts.2010.240747.
PubMed Web of Science ®Google Scholar
Elasfar A, Jalali K, Hussein M, et al. Discontinuation of anticoagulant therapy for a month in a patient with HeartMate III continuous-flow left ventricular assist device without thromboembolic events. J Saudi Heart Assoc. 2018;30(3):268–270. doi: 10.1016/j.jsha.2017.12.002.
PubMed Web of Science ®Google Scholar
Loyaga-Rendon RY, Kazui T, Acharya D. Antiplatelet and anticoagulation strategies for left ventricular assist devices. Ann Transl Med. 2021;9(6):521. doi: 10.21037/atm-20-4849.
PubMed Web of Science ®Google Scholar
Del Rio-Pertuz G, Nair N. Gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices: a comprehensive review. Artif Organs. 2023;47(1):12–23. doi: 10.1111/aor.14432.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Committed to improving the lives of patients with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease.

A bold vision to stop cardiovascular disease from being a leading cause of death.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Durable LVAD in a SLE patient – no anticoagulation for >6 years

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Durable LVAD in a SLE patient – no anticoagulation for >6 years

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date